Context Therapeutics (CNTX) Competitors $0.74 +0.00 (+0.42%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.76 +0.03 (+4.04%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. NBTX, PRQR, SLRN, TVGN, MNPR, SXTC, SLS, EDIT, DSGN, and TVRDShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Nanobiotix (NBTX), ProQR Therapeutics (PRQR), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Monopar Therapeutics (MNPR), China SXT Pharmaceuticals (SXTC), SELLAS Life Sciences Group (SLS), Editas Medicine (EDIT), Design Therapeutics (DSGN), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors Nanobiotix ProQR Therapeutics Acelyrin Semper Paratus Acquisition Monopar Therapeutics China SXT Pharmaceuticals SELLAS Life Sciences Group Editas Medicine Design Therapeutics Tvardi Therapeutics Context Therapeutics (NASDAQ:CNTX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Do institutionals & insiders hold more shares of CNTX or NBTX? 14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 3.0% of Context Therapeutics shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is CNTX or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -29.78% -29.08% Nanobiotix N/A N/A N/A Which has more volatility & risk, CNTX or NBTX? Context Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Does the media prefer CNTX or NBTX? In the previous week, Context Therapeutics and Context Therapeutics both had 1 articles in the media. Context Therapeutics' average media sentiment score of 1.87 beat Nanobiotix's score of 0.93 indicating that Context Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Context Therapeutics Very Positive Nanobiotix Positive Which has stronger valuation & earnings, CNTX or NBTX? Context Therapeutics has higher earnings, but lower revenue than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$26.73M-$0.31-2.37Nanobiotix$39.18M6.36-$73.73MN/AN/A Do analysts rate CNTX or NBTX? Context Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 647.99%. Nanobiotix has a consensus price target of $8.00, suggesting a potential upside of 51.37%. Given Context Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Context Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryContext Therapeutics beats Nanobiotix on 7 of the 12 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.68M$2.44B$5.61B$9.29BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-2.379.1428.5419.58Price / SalesN/A683.96430.1194.56Price / CashN/A164.3436.0257.93Price / Book0.584.608.145.54Net Income-$26.73M$30.99M$3.24B$257.73M7 Day Performance16.34%-1.81%0.17%-0.08%1 Month Performance20.64%5.73%5.95%8.09%1 Year Performance-66.42%-7.03%26.22%13.02% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.3178 of 5 stars$0.74+0.4%$5.50+648.0%-66.6%$65.68MN/A-2.377Positive NewsNBTXNanobiotix2.3233 of 5 stars$4.75-2.5%$8.00+68.6%-3.4%$229.54M$39.18M0.00100PRQRProQR Therapeutics2.3666 of 5 stars$2.14-1.8%$8.00+273.8%+34.9%$229.36M$20.46M-6.11180SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135TVGNSemper Paratus Acquisition3.9645 of 5 stars$1.20-3.2%$10.00+733.3%+69.0%$228.03MN/A0.003Gap DownMNPRMonopar Therapeutics2.1711 of 5 stars$37.20+2.6%$60.00+61.3%+1,020.0%$221.68MN/A-10.6910SXTCChina SXT Pharmaceuticals0.9224 of 5 stars$1.69-10.1%N/A-82.3%$218.13M$1.93M0.0090SLSSELLAS Life Sciences Group0.358 of 5 stars$2.17flatN/A+74.3%$216.52M$1M-5.7110News CoverageHigh Trading VolumeEDITEditas Medicine4.2257 of 5 stars$2.54-1.2%$4.70+85.0%-51.0%$215.14M$32.31M-0.84230DSGNDesign Therapeutics0.533 of 5 stars$3.54-6.1%$4.00+13.0%-12.5%$214.02MN/A-3.5840TVRDTvardi TherapeuticsN/A$21.52-4.2%$71.50+232.2%N/A$210.25M$7.14M0.0080News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies NBTX Alternatives PRQR Alternatives SLRN Alternatives TVGN Alternatives MNPR Alternatives SXTC Alternatives SLS Alternatives EDIT Alternatives DSGN Alternatives TVRD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
